Zobrazeno 1 - 10
of 39
pro vyhledávání: '"Keith, Friend"'
Autor:
Alpesh Amin, Alessandra B Garcia Reeves, Xiaoyan Li, Amol Dhamane, Xuemei Luo, Manuela Di Fusco, Anagha Nadkarni, Keith Friend, Lisa Rosenblatt, Jack Mardekian, Xianying Pan, Huseyin Yuce, Allison Keshishian
Publikováno v:
PLoS ONE, Vol 14, Iss 3, p e0213614 (2019)
Direct oral anticoagulants (DOACs) are at least as efficacious and safe as warfarin among non-valvular atrial fibrillation (NVAF) patients; limited evidence is available regarding NVAF patients with heart failure (HF). US Medicare enrollees with NVAF
Externí odkaz:
https://doaj.org/article/ab555b9c360b40b4888492a4a3d66bf9
Autor:
Xiaoyan Li, Allison Keshishian, Melissa Hamilton, Ruslan Horblyuk, Kiran Gupta, Xuemei Luo, Jack Mardekian, Keith Friend, Anagha Nadkarni, Xianying Pan, Gregory Y H Lip, Steve Deitelzweig
Publikováno v:
PLoS ONE, Vol 13, Iss 1, p e0191722 (2018)
Prior real-world studies have shown that apixaban is associated with a reduced risk of stroke/systemic embolism (stroke/SE) and major bleeding versus warfarin. However, few studies evaluated the effectiveness and safety of apixaban according to its d
Externí odkaz:
https://doaj.org/article/76704cb3a6c24baa8c05be1ecbffad32
Autor:
Mary M. DeSouza, Naoki Sato, Paul D. Kessler, Hela Romdhani, Annie Guerin, Raluca Ionescu-Ittu, Maria Borentain, Keith Friend, Lei Chen
Publikováno v:
Cardiology and Therapy
Introduction This study described patients hospitalized for acute heart failure (AHF) in Japan who received intravenous (IV) diuretics and/or vasodilators as the initial therapy. Methods The Japan Medical Data Vision database was used to identify adu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::208b29bcdc40b24b68488146e117f310
https://doi.org/10.1007/s40119-021-00212-y
https://doi.org/10.1007/s40119-021-00212-y
Autor:
Jack Mardekian, W. Schuyler Jones, Renato D. Lopes, Keith Friend, Xianying Pan, Allison Keshishian, Xuemei Luo, Jan Steffel, Xiaoyan Li, Kiran Gupta, Cristina Masseria, Onur Baser, Melissa Hamilton, Manuela Di Fusco
Publikováno v:
The American Journal of Medicine. 133:1229-1238
Results There were 33,269 apixaban-warfarin, 9,345 dabigatran-warfarin, and 42,156 rivaroxaban-warfarin matched pairs, with a median follow-up of 4-5 months. Compared with warfarin, apixaban was associated with lower rates of stroke/systemic embolism
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0e31166093cb38ac65fe8b404d46e011
https://doi.org/10.1016/j.amjmed.2020.06.003
https://doi.org/10.1016/j.amjmed.2020.06.003
Autor:
Gail Wygant, Xiaoyan Li, Andreas Nikolaou, Mustafa Oguz, Daniel E. Singer, Patrick Hlavacek, Keith Friend, T. Lanitis, Soeren Mattke
Publikováno v:
Applied Health Economics and Health Policy
Background There is limited evidence on the clinical and cost benefits of screening for atrial fibrillation (AF) with electrocardiogram (ECG) in asymptomatic adults. Methods We adapted a previously published Markov model to evaluate the clinical and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af9489d8e454a42d604d161ba1f4f281
https://doi.org/10.1007/s40258-019-00542-y
https://doi.org/10.1007/s40258-019-00542-y
Autor:
Xiaoyan Li, Xuemei Luo, W. Schuyler Jones, Xianying Pan, Cristina Masseria, Laine Thomas, Renato D. Lopes, Jack Mardekian, Manuela Di Fusco, Huseyin Yuce, Keith Friend, Allison Keshishian
Publikováno v:
The American journal of cardiology. 148
To address literature gaps on treatment with real-world evidence, this study compared effectiveness, safety, and cost outcomes in NVAF patients with coronary or peripheral artery disease (CAD, PAD) prescribed apixaban versus other oral anticoagulants
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b2cd5f8355b97cad99eee286b32aeb7
https://pubmed.ncbi.nlm.nih.gov/33667438
https://pubmed.ncbi.nlm.nih.gov/33667438
Autor:
Jack Mardekian, Xuemei Luo, Melissa Hamilton, Anagha Nadkarni, Xiaoyan Shawn Li, Steve Deitelzweig, Xianying Pan, Keith Friend, Gregory Y.H. Lip, Allison Keshishian, Kiran Gupta, Ruslan Horblyuk
Publikováno v:
Li, X, Deitelzweig, S, Keshishian, A, Hamilton, M, Horblyuk, R, Gupta, K, Luo, X, Mardekian, J, Friend, K, Nadkarni, A, Pan, X & Lip, G Y H 2017, ' Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in "real-world" clinical practice : A propensity-matched analysis of 76,940 patients ', Thrombosis and Haemostasis, vol. 117, no. 6, pp. 1072-1082 . https://doi.org/10.1160/TH17-01-0068
Thrombosis and Haemostasis
Thrombosis and Haemostasis
SummaryThe ARISTOTLE trial showed a risk reduction of stroke/systemic embolism (SE) and major bleeding in non-valvular atrial fibrillation (NVAF) patients treated with apixaban compared to warfarin. This retrospective study used four large US claims
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::944cb5888c10c65f6c469f0f9875d8dd
https://doi.org/10.1160/th17-01-0068
https://doi.org/10.1160/th17-01-0068
Autor:
Gregory Y H, Lip, Allison, Keshishian, Xiaoyan, Li, Melissa, Hamilton, Cristina, Masseria, Kiran, Gupta, Xuemei, Luo, Jack, Mardekian, Keith, Friend, Anagha, Nadkarni, Xianying, Pan, Onur, Baser, Steven, Deitelzweig
Publikováno v:
Stroke. 49(12)
Background and Purpose- This ARISTOPHANES study (Anticoagulants for Reduction in Stroke: Observational Pooled Analysis on Health Outcomes and Experience of Patients) used multiple data sources to compare stroke/systemic embolism (SE) and major bleedi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::60b692d09a5b74c557bc25c176653665
https://pubmed.ncbi.nlm.nih.gov/32202989
https://pubmed.ncbi.nlm.nih.gov/32202989
Autor:
Cristina Masseria, W. Schuyler Jones, Melissa Hamilton, Xianying Pan, Keith Friend, Allison Keshishian, Xiaoyan Li, Onur Baser, Xuemei Luo, Renato D. Lopes, Jack Mardekian, Jan Steffel, Kiran Gupta, Manuela Di Fusco
Background Direct oral anticoagulants (DOAC) are at least non-inferior to warfarin in efficacy and safety among patients with nonvalvular atrial fibrillation. Limited evidence is available regarding outcomes for nonvalvular atrial fibrillation patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95e3955175139c82147f730ba605f021
https://www.zora.uzh.ch/id/eprint/162587/
https://www.zora.uzh.ch/id/eprint/162587/
Autor:
Jack Mardekian, Anagha Nadkarni, O Baser, Xiaoyan Li, Xianying Pan, Xuemei Luo, Amol D Dhamane, Steven Deitelzweig, G Y H Lip, Keith Friend, Melissa Hamilton, Cristina Masseria, A Keshishian
Publikováno v:
European Heart Journal. 39
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::94fde4fb1c7e5576a167349ad754b997
https://doi.org/10.1093/eurheartj/ehy565.p2568
https://doi.org/10.1093/eurheartj/ehy565.p2568